Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03054363 |
|
Recruitment Status :
Recruiting
First Posted : February 15, 2017
Last Update Posted : May 4, 2020
|
Sponsor:
University of Colorado, Denver
Collaborator:
Academic Breast Cancer Research Consortium (ABRCC)
Information provided by (Responsible Party):
University of Colorado, Denver
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Actual Primary Completion Date : | March 18, 2020 |
| Estimated Study Completion Date : | October 31, 2020 |